Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma

BackgroundThe COMPASSION-15 trial demonstrated that cadonilimab plus chemotherapy (CAD-CHM) confers clinical benefits over placebo plus chemotherapy (PLA-CHM) as a first-line treatment for human epidermal growth factor receptor 2 (HER2)-negative advanced gastric or gastroesophageal junction (G/GEJ)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zhifeng Zhou, Yanqing Yang, Shaofang Chen, Maojin You
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2025-05-01
Colecção:Frontiers in Immunology
Assuntos:
cadonilimab
chemotherapy
cost-effectiveness
first-line treatment
HER2-negative
gastric or gastroesophageal junction adenocarcinoma
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1575627/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados